| Item Type | Name |
|
Concept
|
Serotonin Antagonists
|
|
Concept
|
Serotonin
|
|
Concept
|
Receptors, Serotonin, 5-HT3
|
|
Concept
|
Serotonin 5-HT3 Receptor Antagonists
|
|
Concept
|
Serotonin Receptor Agonists
|
|
Academic Article
|
Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
|
|
Academic Article
|
The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
|
|
Academic Article
|
Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
|
|
Academic Article
|
Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists.
|
|
Academic Article
|
Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
|
|
Academic Article
|
Emerging drugs for chemotherapy-induced emesis.
|
|
Academic Article
|
Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
|
|
Academic Article
|
Prevention of emesis from multiple-day and high-dose chemotherapy regimens.
|
|
Academic Article
|
Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
|
|
Academic Article
|
Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial.
|
|
Academic Article
|
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer.
|
|
Academic Article
|
Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.
|
|
Academic Article
|
Antiemetic control: toward a new standard of care for emetogenic chemotherapy.
|
|
Academic Article
|
Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials.
|
|
Academic Article
|
New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations.
|
|
Academic Article
|
The current status of the use of palonosetron.
|
|
Academic Article
|
Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents.
|
|
Academic Article
|
Palonosetron for the treatment of chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy.
|
|
Academic Article
|
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
|
|
Academic Article
|
Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting.
|
|
Academic Article
|
Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients.
|
|
Academic Article
|
Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis.
|
|
Academic Article
|
Do we still need to study palonosetron for chemotherapy-induced nausea and vomiting? A cumulative meta-analysis.
|
|
Academic Article
|
Efficacy of intravenous NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies.
|
|
Academic Article
|
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
|